Sivik Global Healthcare LLC Decreases Holdings in McKesson Co. (NYSE:MCK)

Sivik Global Healthcare LLC reduced its position in McKesson Co. (NYSE:MCK - Free Report) by 14.3% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 15,000 shares of the company's stock after selling 2,500 shares during the quarter. McKesson comprises approximately 2.9% of Sivik Global Healthcare LLC's investment portfolio, making the stock its 11th biggest holding. Sivik Global Healthcare LLC's holdings in McKesson were worth $6,945,000 at the end of the most recent quarter.

A number of other large investors have also made changes to their positions in MCK. U.S. Capital Wealth Advisors LLC increased its holdings in shares of McKesson by 2.5% during the third quarter. U.S. Capital Wealth Advisors LLC now owns 1,757 shares of the company's stock valued at $764,000 after acquiring an additional 43 shares in the last quarter. Valeo Financial Advisors LLC increased its stake in McKesson by 6.8% during the 3rd quarter. Valeo Financial Advisors LLC now owns 1,198 shares of the company's stock valued at $521,000 after purchasing an additional 76 shares in the last quarter. PDS Planning Inc raised its holdings in shares of McKesson by 3.5% in the third quarter. PDS Planning Inc now owns 865 shares of the company's stock worth $376,000 after buying an additional 29 shares during the last quarter. Commonwealth Equity Services LLC lifted its stake in shares of McKesson by 2.1% during the third quarter. Commonwealth Equity Services LLC now owns 61,484 shares of the company's stock worth $26,737,000 after buying an additional 1,268 shares during the period. Finally, RMR Wealth Builders purchased a new stake in shares of McKesson during the third quarter valued at $286,000. 85.07% of the stock is owned by institutional investors and hedge funds.

McKesson Price Performance

MCK stock traded up $1.12 during mid-day trading on Tuesday, reaching $537.21. 664,707 shares of the company's stock were exchanged, compared to its average volume of 692,815. The company has a market cap of $70.59 billion, a price-to-earnings ratio of 24.34, a price-to-earnings-growth ratio of 1.44 and a beta of 0.45. McKesson Co. has a 12-month low of $352.34 and a 12-month high of $544.81. The stock's 50 day moving average is $529.26 and its 200 day moving average is $491.02.

McKesson (NYSE:MCK - Get Free Report) last released its quarterly earnings results on Wednesday, February 7th. The company reported $7.74 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $7.05 by $0.69. McKesson had a net margin of 0.99% and a negative return on equity of 262.63%. The firm had revenue of $80.90 billion for the quarter, compared to analysts' expectations of $77.93 billion. During the same quarter last year, the company earned $6.90 EPS. The firm's revenue for the quarter was up 14.8% compared to the same quarter last year. On average, research analysts forecast that McKesson Co. will post 27.59 earnings per share for the current fiscal year.

McKesson Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Monday, July 1st. Stockholders of record on Monday, June 3rd will be given a $0.62 dividend. This represents a $2.48 dividend on an annualized basis and a dividend yield of 0.46%. The ex-dividend date is Friday, May 31st. McKesson's dividend payout ratio (DPR) is 11.24%.

Analyst Upgrades and Downgrades

A number of brokerages have commented on MCK. StockNews.com raised McKesson from a "buy" rating to a "strong-buy" rating in a research report on Thursday, April 25th. Barclays began coverage on McKesson in a report on Wednesday, January 3rd. They set an "overweight" rating and a $537.00 target price for the company. Argus increased their price target on shares of McKesson from $510.00 to $570.00 and gave the stock a "buy" rating in a report on Wednesday, April 10th. UBS Group lifted their price objective on shares of McKesson from $575.00 to $620.00 and gave the company a "buy" rating in a research note on Wednesday, March 6th. Finally, SVB Leerink began coverage on shares of McKesson in a research note on Monday, February 26th. They issued an "outperform" rating and a $600.00 price objective on the stock. Two equities research analysts have rated the stock with a hold rating, ten have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, McKesson currently has an average rating of "Moderate Buy" and a consensus price target of $536.71.

Insiders Place Their Bets

In other McKesson news, CEO Brian S. Tyler sold 3,473 shares of the company's stock in a transaction on Friday, March 15th. The stock was sold at an average price of $524.55, for a total value of $1,821,762.15. Following the completion of the sale, the chief executive officer now directly owns 43,445 shares in the company, valued at approximately $22,789,074.75. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. In other McKesson news, CEO Brian S. Tyler sold 3,473 shares of the business's stock in a transaction dated Friday, March 15th. The shares were sold at an average price of $524.55, for a total value of $1,821,762.15. Following the transaction, the chief executive officer now directly owns 43,445 shares in the company, valued at approximately $22,789,074.75. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Leann B. Smith sold 186 shares of the firm's stock in a transaction that occurred on Tuesday, February 13th. The stock was sold at an average price of $496.00, for a total transaction of $92,256.00. Following the sale, the executive vice president now owns 1,511 shares of the company's stock, valued at approximately $749,456. The disclosure for this sale can be found here. Corporate insiders own 0.21% of the company's stock.

McKesson Profile

McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, Prescription Technology Solutions (RxTS), Medical-Surgical Solutions, and International. The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products.

Want to see what other hedge funds are holding MCK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for McKesson Co. (NYSE:MCK - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.